Claims for Patent: 10,092,706

Summary for Patent: 10,092,706

Title:	Autoinjector apparatus
Abstract:	An autoinjector apparatus is disclosed which comprises a single-use cassette and an autoinjector. The cassette comprises a housing and a sleeve movably disposed in the housing. A syringe may be disposed in the sleeve and secured therein with a lock cap. The lock cap is affixed to a distal end of the sleeve and contacts the distal end of the syringe. A shield remover extends through an opening in a proximal end of the housing for removing a needle shield which covers a needle of the syringe. A cassette identification arrangement is provided on a surface of the housing to enable the autoinjector to identify the cassette. The autoinjector is provided with a detector for reading the cassette identification arrangement.
Inventor(s):	Denzer; Michael (Ringoes, NJ), Swift; Robert W. (Fillmore, CA), Johnston; Neal D. (Dallas, TX), Ganzitti; Gabriele (Milan, IT), Ewing; Kenneth R. (Fremont, CA), Krishna; Suhas (Simi Valley, CA)
Assignee:	AMGEN INC. (Thousand Oaks, CA)
Application Number:	14/112,479
Patent Claims:	1. A single-use cassette for use with an autoinjector, the cassette comprising: a housing; an inner sleeve disposed in the housing and movable between first and second positions, a syringe disposed in the inner sleeve; a lock cap for securing the syringe in the inner sleeve, the lock cap including an elastomeric bumper, the lock cap affixed to a distal end of the inner sleeve with the elastomeric bumper contacting a distal end of the syringe, wherein the distal end of the inner sleeve comprises at least one receptacle and the lock cap comprises at least one arm member for inserting into the receptacle; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe, wherein the shield remover comprises an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue that expands outwardly when the shield remover is removed from the cassette to prevent the shield remover from being reinserted into the cassette. 2. The cassette of claim 1, wherein the at least one arm member of the lock cap comprises a barb arrangement for gripping an inner surface of the at least one receptacle of the inner sleeve. 3. The cassette of claim 1, wherein the shield remover comprises a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing. 4. The cassette of claim 1, wherein the syringe includes a barrel and an injection needle. 5. The cassette of claim 1, further comprising a therapeutic product in the syringe. 6. The cassette of claim 5, wherein the therapeutic product is selected from the group consisting of Epogen.RTM., Aranesp.RTM., Enbrel.RTM., Neulasta.RTM., Neupogen.RTM., Nplate.RTM., Vectibix.RTM., Sensipar.RTM., Xgeva.RTM. and Prolia.RTM.. 7. The cassette of claim 5, wherein the therapeutic product is an antibody to IL-17 Receptor A, an antagonist of angiopoietin-2, a TNF blocker or inhibitor. 8. The cassette of claim 7, wherein the therapeutic product is a TNF blocker or inhibitor and is etanercept, adalimumab, certolizumab, golimumab or infliximab. 9. The cassette of claim 1, further comprising a cassette identification arrangement on a surface of the housing to enable the autoinjector to identify the cassette. 10. The cassette of claim 9, wherein the cassette identification arrangement comprises at least one projection. 11. An apparatus for injection of a therapeutic product, the apparatus comprising: an autoinjector; and a single-use cassette for use with the injector, the cassette comprising: a housing; an inner sleeve disposed in the housing and movable between first and second positions; a syringe disposed in the inner sleeve; a lock cap for securing the syringe in the inner sleeve, the lock cap including an elastomeric bumper, the lock cap affixed to a distal end of the inner sleeve with the elastomeric bumper contacting a distal end of the syringe, wherein the distal end of the inner sleeve comprises at least two receptacles and the lock cap comprises at least arm members, each inserted into one of the receptacles; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe, wherein the shield remover comprises a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing to prevent removal of the shield remover from the cassette, and wherein the shield remover comprises an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue that expands outwardly when the shield remover is removed from the cassette to prevent the shield remover from being reinserted into the cassette. 12. The apparatus of claim 11, wherein each arm member of the lock cap comprises a barb arrangement for gripping an inner surface of the corresponding receptacle of the inner sleeve. 13. The apparatus of claim 11, wherein the shield remover comprises a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing to prevent removal of the shield remover from the cassette. 14. The apparatus of claim 13, wherein the autoinjector comprises a pin for pushing the tab out of the aperture defined in the wall of the housing when the cassette is placed in the injector to thereby allow the shield remover to be removed from the cassette. 15. The apparatus of claim 11, further comprising a therapeutic product in the syringe. 16. The apparatus of claim 15, wherein the therapeutic product is selected from the group consisting of Epogen.RTM., Aranesp.RTM., Enbrel.RTM., Neulasta.RTM., Neupogen.RTM., Nplate.RTM., Vectibix.RTM., Sensipar.RTM., Xgeva.RTM., and Prolia.RTM.. 17. The apparatus of claim 15, wherein the therapeutic product is an antibody to IL-17 Receptor A, an antagonist to angiopoietin-2, or a TNF blocker or inhibitor. 18. The apparatus of claim 15, wherein the therapeutic product is a TNF blocker or inhibitor and is etanercept, adalimumab, certolizumab, golimumab or infliximab. 19. The apparatus of claim 11, further comprising a cassette identification arrangement on a surface of the housing to enable the autoinjector to identify the cassette. 20. The apparatus of claim 19, wherein the cassette identification arrangement comprises at least one projection or a detector for reading the cassette identification arrangement to identify the cassette. 21. An apparatus for injection of a therapeutic product, the apparatus comprising: an autoinjector; and a single-use cassette for use with the injector, the cassette comprising: a housing; a sleeve disposed in the housing and movable between first and second positions; a syringe disposed in the sleeve; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe, the shield remover comprising a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing to prevent removal of the shield remover from the cassette; wherein the autoinjector comprises a pin for pushing the tab out of the aperture defined in the wall of the housing when the cassette is placed in the injector to thereby allow the shield remover to be removed from the cassette. 22. The apparatus of claim 21, wherein the shield remover comprises a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing to prevent removal of the shield remover from the cassette. 23. The apparatus of claim 21, wherein the shield remover comprises an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue that expands outwardly when the shield remover is removed from the cassette to prevent the shield remover from being reinserted into the cassette. 24. The apparatus of claim 21, further comprising a therapeutic product in the syringe, wherein the therapeutic product is Epogen.RTM., Aranesp.RTM., Enbrel.RTM., Neulasta.RTM., Neupogen.RTM., Nplate.RTM., Vectibix.RTM., Sensipar.RTM., Xgeva.RTM., Prolia.RTM., an antibody to IL-17 Receptor A, an antagonist to angiopoietin-2, a TNF blocker or inhibitor, etanercept, adalimumab, certolizumab, golimumab, or infliximab. 25. A single-use cassette for use with an autoinjector, the cassette comprising: a housing; a sleeve disposed in the housing and movable between first and second positions, wherein the sleeve is capable of having a syringe disposed therein; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe, the shield remover comprising an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue that expands outwardly when the shield remover is removed from the cassette to prevent the shield remover from being reinserted into the cassette. 26. The cassette of claim 25, wherein the shield remover comprises a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing to prevent removal of the shield remover from the cassette. 27. The cassette of claim 25, further comprising a syringe disposed in the sleeve, wherein the syringe includes a barrel and an injection needle. 28. The cassette of claim 27, further comprising a therapeutic product in the syringe, wherein the therapeutic product is Epogen.RTM., Aranesp.RTM., Enbrel.RTM., Neulasta.RTM., Neupogen.RTM., Nplate.RTM., Vectibix.RTM., Sensipar.RTM., Xgeva.RTM. and Prolia.RTM., an antibody to IL-17 Receptor A, an antagonist of angiopoietin-2, a TNF blocker or inhibitor, etanercept, adalimumab, certolizumab, golimumab, or infliximab. 29. The cassette of claim 28, wherein the therapeutic product is etanercept. 30. An apparatus for injection of a therapeutic product, the apparatus comprising: an autoinjector; and a single-use cassette for use with the injector, the cassette comprising: a housing; a sleeve disposed in the housing and movable between first and second positions; a syringe disposed in the sleeve; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe, the shield remover comprising an elongated body having a proximal end and a distal end, the distal end comprising at least one flexible tongue that expands outwardly when the shield remover is removed from the cassette to prevent the shield remover from being reinserted into the cassette. 31. The apparatus of claim 30, wherein the shield remover comprises a spring-biased tab, the tab disposed within an aperture defined in a wall of the housing to prevent removal of the shield remover from the cassette. 32. The apparatus of claim 30, wherein the autoinjector comprises a pin for pushing the tab out of the aperture defined in the wall of the housing when the cassette is placed in the injector to thereby allow the shield remover to be removed from the cassette. 33. The apparatus of claim 30, further comprising a therapeutic product in the syringe, wherein the therapeutic product is Epogen.RTM., Aranesp.RTM., Enbrel.RTM., Neulasta.RTM., Neupogen.RTM., Nplate.RTM., Vectibix.RTM., Sensipar.RTM., Xgeva.RTM., Prolia.RTM., an antibody to IL-17 Receptor A, an antagonist to angiopoietin-2, a TNF blocker or inhibitor, etanercept, adalimumab, certolizumab, golimumab, or infliximab. 34. The apparatus of claim 33, wherein the therapeutic product is etanercept.

Details for Patent 10,092,706

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2031-04-20
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2031-04-20
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2031-04-20
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2031-04-20
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2031-04-20